A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.

Condition:   AnemiaInterventions:   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta);   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor:   Hoffmann-La RocheActive, not recruiting - verified December 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials